Related coverage linked through entity extraction aliases.
Jun 26, 2026
Studies reveal context-dependent genetic effects in psychiatric disorders, reassuring evidence on prenatal antidepressant use, and findings on parental depression timing, diagnostic interview reliability, and rising self-diagnosis.
May 16, 2026
The TGA warned about the risk of homicidal ideation associated with atomoxetine in paediatric patients and published its February 2026 Product Information safety updates. The updates cover multiple medicines with changes to contraindications, warnings and adverse effects. Nearly one in five Australians took a prescription psychiatric drug in 2023-24.
Aug 01, 2026
New studies show rapid expansion of ADHD drug prescribing, with US youth psychiatric drug use rising from 5.3% to 8.3% and Ontario stimulant prescriptions surging 175% during COVID.
Jul 03, 2026
The FDA will allow food makers to claim "no artificial colors" as long as dyes are not petroleum-based, even if products contain titanium dioxide. Health experts warn the labeling deceives consumers, as naturally derived additives like titanium dioxide pose health risks and remain unregulated.
Jun 25, 2026
Otsuka's ADHD drug centanafadine met the primary endpoint in a Phase 3b trial in adults with comorbid anxiety, with results supporting its efficacy ahead of a July 24, 2026 FDA decision. The FDA has granted priority review to the New Drug Application for the first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). If approved, centanafadine would be a novel treatment option for ADHD in children, adolescents, and adults.
Apr 23, 2026
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
